Verzenios 150mg

                  Verzenios 150mg

Abemaciclib (brand name Verzenio) is a drug for the treatment of metastatic breast cancer. Developed by Eli Lilly, it is a selective inhibitor of the enzymes CDK4 and CDK6. The US Food and Drug Administration approved the drug on December 28, 2017 for the treatment of certain types of breast cancer.

Uses:

This medication is prescribed for adults with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease is progressing despite hormonal therapy.